Click here to view video highlights from this interview. AJMC ®: What stands out in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America ...
Please provide your email address to receive an email when new articles are posted on . In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from ...
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure. A 56-year-old man with a history of hypertension and type 2 ...
The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients hospitalized with heart failure (HF) and a left ventricular ejection fraction > 40% increased substantially within 2 years ...
A new joint guideline published today from the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America, increases the focus on preventing heart failure ...
Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we ...
The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...
Please provide your email address to receive an email when new articles are posted on . In this video, Javed Butler, MD discusses research on SGLT2 inhibitors presented at the American Heart ...
Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data that show the drug’s effectiveness ...
The new guidelines also call for better incorporation and addressing of social determinants of health. During a panel at the American College of Cardiology’s (ACC) 70th Scientific Session, experts ...
Some heart failure patients had arguably better outcomes after simultaneous initiation of an SGLT2 inhibitor plus a mineralocorticoid receptor antagonist (MRA) in the SOGALDI-PEF trial, but safety ...
People with symptomatic heart failure may be able to reduce their risk of premature death by taking a drug originally designed for type 2 diabetes, according to new treatment guidelines from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback